Precision Medicine in Oncology® | Specialty

Adjuvant Therapy Options in Advanced Melanoma

December 9th 2016

Case 3: Post-Surgical Recurrent Melanoma

December 9th 2016

Melanoma: Nuances of BRAF/MEK Combinations in the Front line

December 9th 2016

Sequencing Decisions and Multidisciplinary Care in Metastatic Melanoma

December 9th 2016

Patient Selection in Melanoma: Immunotherapy vs Targeted Therapy

December 9th 2016

Achieving Durable Responses in Advanced Melanoma

December 9th 2016

Case 2: Frontline Decisions in Stage IV BRAF-mutant Melanoma

December 9th 2016

Immunotherapy in Melanoma: Managing Toxicities

December 9th 2016

Melanoma: Helping Patients Understand Immunotherapy

December 9th 2016

Case I: Newly Diagnosed BRAF Wild Type Advanced Melanoma

December 9th 2016

The Current Understanding of Biomarkers in Melanoma

December 9th 2016

Dr. Lindeman on RANK Ligand as Breast Cancer Prevention Target in BRCA1 Carriers

December 8th 2016

Geoffrey Lindeman, MD, joint head, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research, discusses a study exploring RANK ligand as a target for breast cancer prevention in patients who harbor the BRCA1 mutation.

TILs Associated With Survival for Advanced HER2+ Breast Cancer

December 8th 2016

Higher levels of tumor-infiltrating lymphocytes were associated with improvements in overall survival for patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab in the phase III CLEOPATRA trial.

Veliparib Regimen Nears 80% Response Rate in BRCA+ Breast Cancer

December 8th 2016

Adding the PARP inhibitor veliparib to carboplatin/paclitaxel chemotherapy induced a response rate of 77.8% in patients with advanced BRCA-positive breast cancer.

Passed by House, 21st Century Cures Act Could Spur Advances, Weaken FDA

December 2nd 2016

Viewed by some as a boon for precision medicine, an Alzheimer’s cure, brain research, and opioid abuse prevention, but also seen as weakening the FDA’s regulatory power, the $6.3 billion 21st Century Cures Act passed overwhelmingly in the House Wednesday by a vote of 392-26.

Investigating EGFR Resistance Leads to New Therapies, Advances in NSCLC

November 23rd 2016

While resistance to EGFR-targeted therapies in non–small cell lung cancer presents a major challenge, there is a silver lining.

Expert Discusses the Future of Circulating Biomarkers in Prostate Cancer

November 23rd 2016

Biomarkers play a key role in the optimization of treatments for patients with prostate cancer. According to Mark Stein, MD, they can even serve as clinical endpoints in trials.

Looming Questions, Challenges Facing Physicians in Prostate Cancer

November 22nd 2016

Identifying biomarkers to determine who should receive chemotherapy, targeted agents, and immunotherapy is just one of several obstacles the prostate cancer community is currently facing.

Big Data Triggers Revolution in Discovery

November 22nd 2016

In the old days, not too long ago, doctors’ offices were full of paper records, which filled shelf after shelf. This cumbersome form of keeping track of patients was effective in its own way, but with the rise of modern medicine and the power of computing, there is a need to move beyond.

Biomarkers, Combo Regimens Key to Mitigating AR-Resistance in mCRPC

November 21st 2016

A number of clinical trials are seeking to identify beneficial therapeutic outcomes in patients with prostate cancer who are resistant to androgen receptor–targeted agents.